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Abstract
Objective: This study aimed to determine the current state of antifungal prophylaxis in Turkish stem 
cell transplantation (SCT) centers. 
Materials and Methods: The were 38 active stem cell transplantation centers in Turkey, 28 of which were 
registered with the European Group for Blood and Marrow Transplantation (EBMT). Survey question-
naires were sent to the 28 EBMT centers in an effort to collect data on antifungal prophylaxis in different 
settings. In all, 24 of the centers completed the survey; 1 of the 24 centers was excluded from the study, 
as it was under construction at the time and was not performing transplantation.
Results: In all, 15 (65%) of the 23 centers were adult SCT centers, 7 (31%) were pediatric SCT centers, 
and 1 center treated both adult and pediatric patients. All centers (23/23) performed both allogeneic and 
autologous transplants, 20 centers performed non-myeloablative transplants, 8 performed cord blood 
transplants, and 7 performed unrelated transplants. Primary antifungal prophylaxis was used at all 23 
centers during allogeneic transplants, whereas 18 of the 23 centers used it during every autologous 
transplant and 2 of the 23 centers used it during autologous transplants on a per case basis. The most 
common drug used for prophylaxis was fluconazole (F) (21/23), followed by itraconazole (I) (3/23), 
amphotericin-B (2/23), and posaconazole (1/23). Among the 23 centers, 3 reported that for allogenic 
transplants they changed the antifungal prophylactic in cases of graft versus host disease (GVHD), and 
12 of the 23 centers reported that they changed the antifungal prophylactic in case of nearby construc-
tion. All 23 centers performed secondary prophylaxis. 
Conclusion: Antifungal prophylaxis for hematopoetic SCT patients was the standard protocol in the 23 
centers included in the study, usually with such azoles as F. The introduction of posaconazole in Turkey 
and the potential approval of voriconazole for antifungal prophylaxis will eventually alter prophylaxis 
practice in Turkey, which we plan to assess in the future. (Turk J Hematol 2011; 28: 271-5)
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Özet
Amaç: Türkiye’deki kök hücre nakli merkezlerinde antifungal profilaksi eğilimlerini anlamak için 
yapılan bu çalışma bir anket çalışmasıdır.
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The results of a recent survey by the Worldwide 
Network  for  Blood  and  Marrow  Transplantation 
show that in 2008 more than 51,000 hematopoietic 
stem cell transplantations (HSCTs) were performed 
by 1400 teams in 72 countries. In Turkey 944 HSCTs 
were performed in 2010 (numbers reported by 19 
European  Group  for  Blood  and  Marrow 
Transplantation [EBMT] centers); 561 were autolo-
gous and 383 were allogeneic HSCTs, and 97 were 
non-myeloablative transplants.
HSCT is a lifesaving technique, especially in the 
treatment of hematological malignancies; however, 
it is associated with a high risk of infections. Fungal 
infections are a major problem and although they 
represent a small fraction of the infection spectrum, 
they  are  associated  with  a  high  risk  of  mortality 
[1-3]. In recent years new methods of treating inva-
sive  fungal  infections  have  been  developed,  but 
they  are  time  consuming,  expensive,  and  have  a 
high risk of severe side effects. Although evidence 
of the benefit of antifungal prophylaxis in the treat-
ment  of  malign  hematological  diseases  is  weak, 
there is sufficient evidence of the positive effect of 
antifungal prophylaxis on morbidity and mortality in 
stem cell transplantation (SCT) [4-6]. 
Fluconazole (F) has been the main agent used 
for  antifungal  prophylaxis  against  Candida  infec-
tions, but it is ineffective against Aspergillus strains, 
which  remains  a  major  problem  due  to  the  high 
rate of mortality associated with invasive aspergil-
losis.  New  drugs  that  are  effective  against  both 
Candida and Aspergillus have been developed; in 
particular, posaconazole seems to be a promising 
agent  for  stem  cell  transplant  patients  with  graft 
versus host disease (GVHD), and many hospitals in 
the  US  and  Europe  regularly  use  this  drug  [6]. 
Posaconazole  has  recently  been  introduced  to 
Turkey and the other candidate azole voriconazole 
is not indicated for prophylaxis. The present study 
aimed to determine the current state of antifungal 
prophylaxis in Turkish SCT centers. The survey will 
be repeated in 3 years to monitor any changes in 
antifungal prophylactic practice following the intro-
duction of new antifungal drugs.
Materials and Methods 
A survey questionnaire was used to collect data 
on the type of center, type of transplants performed, 
drugs and doses used for antifungal prophylaxis, and 
prophylactic strategies. Among the 38 SCT centers in 
Turkey,  28  were  registered  with  EBMT  (Figure  1).   
All 28 centers received the questionnaire, which was 
confirmed by phone, fax, or e-mail. In all, 24 centers 
responded  to  the  survey;  1  of  the  24  centers   
was excluded from the study, as it was under con-
struction at the time and was not performing trans-
plantation.
Results
Center characteristics
In all, 15 (65%) of the 23 centers were adult SCT 
centers, 7 (31%) were pediatric SCT centers, and 1 
Yöntem ve Gereçler: Türkiye’de çalışan 38 kök hücre nakli merkezinden EBMT’ye kayıtlı 28 merkeze 
anket gönderilmiş ve 24 merkezden yanıt alınmıştır. Bir merkez halen inşaat yapımı nedeni ile anketi 
dolduramamıştır. 
Bulgular: Bu merkezlerden 15 tanesi erişkin (%65), 7 tanesi çocuk (%31) ve 1 tanesi erişkin ve çocuk 
nakil merkezidir. Tüm merkezler hem allogeneik, hem de otolog nakil yapmakta olup; 20 merkezde 
nonmyeloablatif, 8 merkezde kordon kanı ve 7 merkezde akraba dışı nakil yapılmaktadır. Tüm mer-
kezlerde allogeneik nakillerde profilaksi yapılırken, 18/23 merkezde otolog nakillerde profilaksi yapıl-
maktadır. 23 merkezden 2'si ise, otolog nakilde olguya göre profilaksi vermektedir. En çok kullanılan 
ajan Flukonazol olup (21/23), bunu Itrakonazol (3/23), amfoterisin-B (2/23), ve posakonazol (1/23) 
izlemektedir. Allogeneik nakil yapılan 3 merkez Graft versus Host Hastalığı varlığında profilaksiyi 
değiştirmekte ve 12/23 merkez yakında inşaat olması durumunda profilaktik yaklaşımlarını değiştir-
mektedir. Tüm merkezler sekonder profilaksi yapmaktadır.
Sonuç: Son yıllardaki gelişmeler bu alandaki yaklaşımları değiştirecek ve Flukonazol yerine yeni tria-
zollerin geçmesine yol açacak niteliktedir. Bu nedenle bu anket 2013 yılında yinelenerek değişim olup 
olmadığı anlaşılacaktır. (Turk J Hematol 2011; 28: 271-5)
Anahtar kelimeler: Profilaksi, antifungal, kök hücre nakli
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(Figure 2). All centers (23/23) performed both allo-
geneic and autologous transplants, 20 centers per-
formed non-myeloablative transplants, 8 performed 
cord blood transplants, and 7 performed unrelated 
transplants. 
Prophylaxis strategies
Primary antifungal prophylaxis was used at all 23 
centers during allogeneic transplantation, whereas 
18 of the 23 centers used it during all autologous 
transplants and 2 of the 23 centers used it during 
autologous  transplants  on  a  per  case  basis.  The 
most  common  drug  used  for  prophylaxis  was  F 
(21/23), followed by itraconazole (I) (3/23), ampho-
tericin-B (2/23), and posaconazole (1/23). For autol-
ogous transplants the most common prophylactic 
drug  was  F  (18/20),  followed  by  I  (3/20),  and 
amphotericin-B (2/20) (Table 1). 
Dose
The median F dose was 400 mg/d for allogeneic 
transplants and 225 mg/d for autologous transplants. 
Duration
Primary prophylaxis most commonly began on d 
0 (-6 and +1) and ended on d 90 (+30-180) in the 
absence of GVHD. In patients with GVHD, the last 
day of prophylaxis was d 180 (60->180). For autolo-
gous transplants prophylaxis began on d 0 (-1 and 
+1) and ended on d 30 (+15-180). 
Change of Approach
Among the 23 centers, 3 reported that for allo-
genic transplants they changed the antifungal pro-
phylactic in cases of GVHD, and 12 (52%) of the 23 
(52%) centers reported that they changed the anti-
fungal prophylactic in case of nearby construction. 
All  23  centers  performed  secondary  prophylaxis 
and voriconazole was used most often (17.5%), fol-
lowed by amphotericin-B (7.2%). 
Diagnosis
For diagnosis of breakthrough fungal infections 
21 of the 23 centers used high-resolution computed 
tomography, 20 used galactomannan, 5 used b-glu-
can, and 1 used molecular diagnostics (PCR).
Physical measures
Among the 23 centers in the study, 22 took care of 
the patients in private rooms, and 10 of the 23 alloge-
neic and 8 of the 23 autologous centers had a laminar 
air flow system. In all, 22 of the 23 allogeneic centers 
and 21 of the 23 autologous centers used HEPA fil-
ters, and 13 of the 23 allogeneic and 11 of the 23 
autologous centers had positive pressure rooms.
Discussion
Although the effectiveness of antifungal prophy-
laxis was established in the 1980s, in recent years 
there have been several new developments. It was 
clearly  shown  that  F  prophylaxis  was  effective  in 
reducing  the  number  of  invasive  fungal  infections 
Table 1. Drugs Used in Antifungal Prophylaxis  
Type of Center  Nantiful  No. of Center/Total
Allogeneic  Fluconazole  21/23
Allogeneic  Itraconazole  3/23
Allogeneic  Amphotericin-B  2/23
Allogeneic  Posaconazole  1/23
Autologuos  Fluconazole  18/20
Autologous  Itraconazole  3/20
Autologous  Amphotericin-B  2/20
Figure 1. Distribution of Stem Cell Transplantation Centers
Figure 2. Type of Stem Cell Transplantation Centers
1.4%
7.31%
15.65
Adult SCT
Pediatric SCT
Adult + Pediatric SCT
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findings prompted the widespread use of F prophy-
laxis. The use of F led to a decrease in the number of 
Candida  infections,  which  was  subsequently  fol-
lowed by an increase in the number of Aspergillus 
infections [1]. The main problem was that F has no 
effect on Aspergillus and Aspergillus infection is asso-
ciated with a very high mortality rate in SCT patients 
[1,2,7-9].  The  need  for  an  antifungal  drug  with  a 
wider spectrum of effect led to the use of I prophy-
laxis in SCT, with some success; however, bioavail-
ability and tolerability issues precluded its use as a 
primary agent for prophylaxis in SCT [10-12].
A study published in 2005 reported that posacon-
azole, a new triazole, was an effective prophylactic 
against  GVHD  in  allogeneic  SCT  patients  [6]. 
Subsequently, major treatment guidelines support-
ed the use of posaconazole in SCT with an A1 level 
recommendation, and use of this approach contin-
ues to increase [13]. Voriconazole may also be a 
good alternative, as it is available in oral form and 2 
recent studies reported its use resulted in decreas-
ing the rate of invasive fungal infection, although it 
did  not  decrease  the  mortality  rate.  Furthermore, 
posaconazole in tablet form, rather than oral sus-
pension, is currently under investigation. In Turkey F 
is  the  primary  prophylactic  drug  used  in  SCT. 
Although a widespread switch to posaconazole is 
expected, as it was introduced to the Turkish mar-
ket during the last quarter of 2010, the present study 
could not measure its affect on antifungal prophy-
lactic treatment in Turkey. 
All responding SCT centers are using secondary 
prophylaxis  with  voriconazole,  largely  due  to  its 
demonstrated  effectiveness  against  aspergillosis 
and oral form. It is noteworthy that most centers 
rely on diagnostic measures rather than empirical 
approach for detecting breakthrough invasive fun-
gal infections. The aim of the present study was to 
evaluate the state of antifungal prophylaxis in SCT 
centers  in  Turkey  and  the  affect  of  forthcoming 
changes in this area will be assessed by repeating 
the survey in the future. 
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